Chronic Hepatitis C Clinical Trials

3 recruiting

Frequently Asked Questions

Common questions about Chronic Hepatitis C clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting

The Efficacy of Vosevi in Treating DAA-experienced Patients

Chronic Hepatitis CMedication Reaction
The Third Affiliated Hospital of Guangzhou Medical University200 enrolled1 locationNCT06180590
Completed

A cluster randomised controlled trial of a MedicineInsight educational quality improvement program to improve the diagnosis and treatment of chronic hepatitis C in Australian general practice - the EQUIP-HEPC trial

Chronic hepatitis C (CHC)
NPS MedicineWise (Not-for-profit)300 enrolled1 locationACTRN12619000508178
Completed
Phase 2

THE HEP573 STUDY: A randomised, double-blind, placebo-controlled clinical trial of silymarin alone, and silymarin combined with antioxidants in chronic hepatitis C

Chronic Hepatitis C
John Hunter Hospital216 enrolled3 locationsACTRN12614000966695
Completed

PUMA: A pilot study to assess the utility of magnetic resonance imaging in the staging of liver fibrosis.

Patients with liver disease due to chronic hepatitis C virus (HCV) infection who have previously undergone a liver transplant (Group A)
Resonance Health Analysis Services30 enrolled1 locationACTRN12612000357853
Recruiting
Phase 1

A Randomized, Double-blind, Placebo-controlled, First-in-human, 3-Part Study of Orally Administered ALS-002158 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dosing and Food-effect in Healthy Volunteers, and Multiple Ascending Dosing in Subjects with Chronic Hepatitis C Genotype 1 Infection.

Chronic Hepatitis C infection
CPR Pharma Services78 enrolled4 locationsACTRN12612000176864
Recruiting
Phase 4

A single-arm, open-label, pilot study evaluating the efficacy and safety of directly observed peginterferon alfa-2a with ribavirin in conjunction with a peer counsellor in patients actively using injecting drugs who have chronic hepatitis C and attend a drug and alcohol centre.

Chronic hepatitis C virus (HCV) infection.Side effects related to chronic Hepatitis C virus (HCV) infection and treatment in active injecting drug users (IDUs).Factors affecting compliance of active injecting drug users (IDUs) for standard pharmacotherapy treatment of chronic Hepatitis C virus (HCV) infection.+1 more
Dr Joe Sasadeusz50 enrolled1 locationACTRN12608000400369
Terminated
Phase 1

A phase Ib study of oglufanide disodium (IM862) in patients with chronic HCV infection

Chronic Hepatitis C
Implicit Bioscience Pty Ltd32 enrolled1 locationACTRN12606000505505
Completed
Phase 4

The Chariot Study

Chronic Hepatitis C genotype 1
Roche Products Pty Ltd816 enrolled1 locationACTRN12605000488606